Trastuzumab Deruxtecan Dosing in Human Epidermal Growth Factor Receptor 2‐Positive Gastric Cancer: Population Pharmacokinetic Modeling and Exposure–Response Analysis
The Journal of Clinical Pharmacology · 2023
DOI: 10.1002/jcph.2295 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2023. Verfasst von Kazutaka Yoshihara und 8 weiteren Autor:innen. Beteiligte Einrichtung: Quantitative Clinical Pharmacology, Daiichi Sankyo Co., Ltd., Tokyo, Japan. Hauptthemen laut MEDLINE: Stomach Neoplasms, Trastuzumab, Erb-b2 Receptor Tyrosine Kinases, Immunoconjugates. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
This study evaluated the benefit/risk of trastuzumab deruxtecan (T‐DXd) 6.4 mg/kg in patients with human epidermal growth factor receptor 2 (HER2)‐positive gastric cancer using pharmacometrics. A population pharmacokinetic (PopPK) model was developed using data from patients with gastric cancer, breast cancer, or other tumors in T‐DXd clinical trials, primarily conducted in Asia. Post hoc model‐estimated pharmacokinetic metrics were used in exposure–efficacy (objective response rates, ORRs) and exposure–safety analyses. The PopPK analysis included 808 patients (217 with gastric cancer, 512 with breast cancer, and 79 with other cancers). In gastric cancer, the T‐DXd 6.4 mg/kg steady‐state exposure metrics were lower compared with 6.4 mg/kg in breast cancer, but were similar to 5.4 mg/kg in breast cancer. Tumor type was selected as a significant covariate on T‐DXd clearance. In exposure–efficacy analysis among 160 patients with gastric cancer, the T‐DXd steady‐state minimum concentration was associated with a confirmed ORR in univariate logistic regression analysis ( P = .023). The model‐predicted confirmed ORRs in gastric cancer were 36.0% (90%CI 29.3% to 43.7%) with 5.4 mg/kg and 40.0% (90%CI 33.1% to 47.6%) with 6.4 mg/kg. Among 808 patients in the exposure–safety analyses, the model‐predicted estimates for the rates of any‐grade interstitial lung disease (ILD) over a period of 180 days were 10.2% (90%CI 8.7% to 12.8%) with 6.4 mg/kg in gastric cancer and 9.7% (90%CI 8.2% to 11.8%) with 5.4 mg/kg in breast cancer. In gastric cancer, the efficacy of T‐DXd was higher at 6.4 mg/kg than at 5.4 mg/kg. Exposure and ILD rates were comparable between 6.4 mg/kg in gastric cancer and 5.4 mg/kg in breast cancer. This study identified T‐DXd 6.4 mg/kg as the recommended dose in HER2‐positive gastric cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Quantitative Clinical Pharmacology, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
- Certara Inc., Melbourne, Australia.
- QuanTx Consulting, Mountain View, CA, USA.
- Quantitative Clinical Pharmacology, Daiichi Sankyo Inc., Basking Ridge, NJ, USA.
ORCID-Profile: Masato Fukae
Zitieren
APA
Yoshihara, K., Kobayashi, Y., Endo, S., Fukae, M., Hennig, S., Kastrissios, H., Kamiyama, E., Garimella, T., & Abutarif, M. (2023). Trastuzumab Deruxtecan Dosing in Human Epidermal Growth Factor Receptor 2‐Positive Gastric Cancer: Population Pharmacokinetic Modeling and Exposure–Response Analysis. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.2295
Vancouver
Yoshihara K, Kobayashi Y, Endo S, Fukae M, Hennig S, Kastrissios H, et al. Trastuzumab Deruxtecan Dosing in Human Epidermal Growth Factor Receptor 2‐Positive Gastric Cancer: Population Pharmacokinetic Modeling and Exposure–Response Analysis. The Journal of Clinical Pharmacology. 2023. doi:10.1002/jcph.2295
BibTeX
@article{Yoshihara2023,
author = {Yoshihara, Kazutaka and Kobayashi, Yoshimasa and Endo, Seiko and Fukae, Masato and Hennig, Stefanie and Kastrissios, Helen and Kamiyama, Emi and Garimella, Tushar and Abutarif, Malaz},
title = {Trastuzumab Deruxtecan Dosing in Human Epidermal Growth Factor Receptor 2‐Positive Gastric Cancer: Population Pharmacokinetic Modeling and Exposure–Response Analysis},
journal = {The Journal of Clinical Pharmacology},
year = {2023},
doi = {10.1002/jcph.2295}
}
EUVIMED